A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Eligible age
18+ yrs
Accepts
All genders
Locations
16 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The main purpose of Part 1 of this study is to assess the efficacy and safety of 3 dose levels of Pirtobrutinib in participants with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), who have received 1-3 lines of treatment including a covalent Bruton tyrosine kinase (BTK) inhibitor. The purpose of Part 2 of this study is to evaluate pirtobrutinib monotherapy in participants with treatment-naïve CLL/SLL with 17p deletions. Participation in Part 1 is expected to last approximately 3 years. Participation in Part 2 is expected to last up to 2 years.
Sponsor: Loxo Oncology, Inc.
You may qualify if…
- ✓ Have confirmed diagnosis of CLL/SLL as defined by iwCLL 2018 criteria.
- ✓ Part 1: Have received prior CLL/SLL treatment
- ✓ Have received at least 1, but not more than 3 lines of prior treatment for CLL/SLL
- ✓ Have received a covalent BTK inhibitor
- ✓ Part 2: Have received no prior treatment for CLL/SLL
- ✓ Part 1 - Known 17p deletion status (positive or negative)
- ✓ Part 2 - Must have 17p deletion (positive)
- ✓ Have a requirement for therapy consistent with iwCLL 2018 criteria for initiation of therapy
You may not qualify if…
- ✕ Have received prior treatment with a BTK degrader or a noncovalent BTK inhibitor
- ✕ Have a history of greater than or equal to (\>=) Grade 3 bleeding due to treatment with a BTK inhibitor
- ✕ Have known or suspected Richter's transformation
- ✕ Have known or suspected history of central nervous system involvement by CLL/SLL
- ✕ Previous or concurrent cancer distinct from CLL/SLL within 3 years before randomization. Exceptions may occur with documented sponsor approval. Examples include:
- ✕ nonmelanoma skin cancer or lentigo malignant melanoma
- ✕ cervical carcinoma in situ
- ✕ localized prostate cancer undergoing active surveillance, and
Where it's recruiting
Chandler
Duarte · Irvine · Palo Alto
Aurora
Miami
Newnan
Waukee
Edgewood
Bethesda
Boston
Gulfport
Henderson
Greenville
Source: ClinicalTrials.gov · NCT06588478 · last updated 2026-11-04